Neue Möglichkeiten der Augenoberflächenrekonstruktion

Fuchsluger, Thomas Armin; Salehi, Sahar; Petsch, Corinna; Bachmann, Björn

doi:10.1007/s00347-013-3010-z

Ophthalmologe

2014

DOI: 10.1007/s00347-013-3010-z

|View full text |Cite

Neue Möglichkeiten der Augenoberflächenrekonstruktion

Thomas Armin Fuchsluger

Sahar Salehi

Corinna Petsch

et al.

Abstract: Although the majority of the described biomaterials are currently still in the experimental stage, a transfer into the clinical routine is conceivable and of great therapeutic interest.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2015

2017

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 6 publications

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Zelltherapeutika – eine innovative Therapieoption in der Ophthalmologie

Bakker

Langer

2015

Bundesgesundheitsbl.

View full text Add to dashboard Cite

Pathological changes and disorders of the cornea are a major cause of severe visual impairment and blindness. Replacement of a pathologically altered cornea with healthy corneal tissue from the eye of a suitable donor is among the most common and successful transplantation procedures in medicine. In Germany, approximately 5000-6000 corneal transplantations are performed each year, but the total demand per year is estimated to be twice as high. With a success rate of 90%, the outcome of cornea transplantation is very favourable. However, long-term maintenance and regeneration of a healthy new cornea requires tissue-specific corneal stem cells residing at the basal layer of the limbus, which is the annular transition zone between the cornea and sclera. When this important limbal stem cell population is destroyed or dysfunctional, a pathological condition known as limbal stem cell deficiency (LSCD) manifests. Limbal stem cell deficiency describes conditions associated with impaired corneal wound healing and regeneration. In this situation, transplantation of healthy limbal stem cells is the only curative treatment approach for restoration of an intact and functional ocular surface. To date, treatment of LSCD presents a great challenge for ophthalmologists. However, innovative, cell-therapeutic approaches may open new, promising treatment perspectives. In February 2015, the European Commission granted marketing authorization to the first stem cell-based treatment in the European Union. The product named Holoclar® is an advanced therapy medicinal product (ATMP) for the treatment of moderate to severe LSCD due to physical and chemical burns in adults. Further cell-based treatment approaches are in clinical development.

show abstract

Zelltherapeutika – eine innovative Therapieoption in der Ophthalmologie

Bakker

Langer

2015

Bundesgesundheitsbl.

View full text Add to dashboard Cite

show abstract

Hornhautchirurgie und Hornhauttransplantation bei Kindern

et al. 2015

View full text Add to dashboard Cite

The surgical treatment of congenital corneal diseases or corneal diseases occurring during infancy is demanding even for experienced corneal surgeons. Besides the need for frequent examinations under anesthesia during the postoperative follow-up in young children and infants (e.g. after corneal transplantation), the surgeon frequently encounters intraoperative and postoperative problems, such as low scleral rigidity, positive vitreous pressure and a narrow anterior chamber. Other problems include increased fibrin reaction, an increased risk of rejection in cases of allogenic corneal transplantation and frequent loosening of sutures necessitating replacement or early removal. Lamellar corneal transplantation reduces the risk of graft rejection and the risk of wound leakage. Moreover, posterior lamellar keratoplasty in children offers a faster visual recovery compared to penetrating keratoplasty and thus reduces the risk of amblyopia.

show abstract

Proteins of the corneal stroma: importance in visual function

et al. 2016

View full text Add to dashboard Cite

The human cornea, consisting of five layers, is the transparent tissue that refracts and transmits light to the lens and retina, providing about two thirds of the refractive power of the eye. The stroma layer comprises nearly 90 % of the thickness of the cornea and thus plays a pivotal role in normal visual function. The bulk of this layer is constituted by proteins in the extracellular martrix secreted by the corneal epithelial, stroma, and endothelial cells. Clinical research has shown that corneal stroma diseases are common and involve conditions such as infections, injuries, and genetic defects, which cause severe visual disturbances or even blindness. To improve our understanding of the basic molecular mechanisms involved in the physiological and pathological activities of the corneal stroma, its proteins have been brought into the limelight to determine their crucial and irreplaceable roles. The data presented in a previous study have demonstrated the presence of 1679 proteins in the stroma, and this data set has subsequently been perfected by utilizing a highly sensitive isobaric peptide-labeling approach. According to their manifestations, these proteins can be classified as a gel-like organic material composed of proteoglycans, enzymes, and hemocyanin-binding proteins and a network of filaments composed of collagen, elastin, keratin, vimentin, and interconnected filaments comprising fibronectin and laminin. The aim of this review is to describe some corneal stroma proteins by highlighting their major functions and valuable applications in ophthalmologic research toward the better characterization and treatment of eye diseases.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Neue Möglichkeiten der Augenoberflächenrekonstruktion

Abstract: Although the majority of the described biomaterials are currently still in the experimental stage, a transfer into the clinical routine is conceivable and of great therapeutic interest.

Cited by 6 publications

References 52 publications

Zelltherapeutika – eine innovative Therapieoption in der Ophthalmologie

Zelltherapeutika – eine innovative Therapieoption in der Ophthalmologie

Hornhautchirurgie und Hornhauttransplantation bei Kindern

Proteins of the corneal stroma: importance in visual function

Contact Info

Product

Resources

About